Using public data, we found that SV2B showed diagnostic efficacy comparable to that of TRIM63 but significantly superior to that of GPNMB in distinguishing TFE3‐RCC from KIRC and KIRP (Figure S1, Supporting Information). This evidence concerns the gene TFE3 and renal cell carcinoma.